Research Spotlight: Iron chelation: Deciphering novel molecular targets for cancer therapy. the tip of the iceberg of a web of iron-regulated molecules

Future Medicinal Chemistry

Volumn 3, Issue 16, 2011, Pages 1983-1986

  Saletta, Federica ^a   Kovacevic, Zaklina ^a   Richardson, Des Raymond ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CCAAT BINDING FACTOR; CYCLIN D1; DEFEROXAMINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; JANUS KINASE; MIMOSINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P21; SYNAPTOPHYSIN; THIOSEMICARBAZONE; UVOMORULIN; IRON; IRON CHELATING AGENT;

ARTICLE; CANCER INHIBITION; ENDOPLASMIC RETICULUM STRESS; HUMAN; IRON CHELATION; IRON DEPLETION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RESEARCH; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; NEOPLASM; PHYSIOLOGY;

HUMANS; IRON; IRON CHELATING AGENTS; NEOPLASMS;

EID: 81855173468     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.154     Document Type: Article

References (20)

1. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma N. Eng. J. Med. 365, 576-578 (2011).
2. Kovacevic Z, Chikhani S, Lovejoy DB, Richardson DR. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 80, 598-609 (2011).
3. Yu Y, Rahmanto YS, Richardson D. Bp44mT: An orally-active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. doi:10.1111/j.1476-5381.2011.01526 (2011) (Epub ahead of print).
4. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl Acad. Sci. USA 103, 14901-14906 (2006).
5. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment, Blood 104, 1450-1458 (2004).
6. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer, Pharmacol. Rev. 57 547-583 (2005).
7. Yu Y, Kalinowski DS, Kovacevic Z et al. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J. Med. Chem. 52, 5271-5294 (2009).
8. Cook JD, Skikne BS, Baynes RD. Iron deficiency: the global perspective. Adv. Exp. Med. Biol. 356 219-228 (1994).
9. Saletta F, Rahmanto YS, Noulsri E, Richardson DR. Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol. Pharmacol. 77, 443-458 (2010).
10. Kovacevic Z, Richardson DR. The metastasis suppressor, Ndrg-1: A new ally in the fight against cancer. Carcinogenesis 27, 2355-2366 (2006).
11. Saletta F, Suryo Rahmanto Y, Siafakas AR, Richardson DR. Cellular iron-depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes. J. Biol. Chem. 286, 35396-35406 (2011).
12. Yu Y, Richardson DR. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1- thioredoxin and activation of ASK1. J. Biol. Chem. 286, 15413-15427 (2011).
13. Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110, 752-761 (2007).
14. Nurtjahja-Tjendraputra E, Fu D, Phang JM, Richardson DR. Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression. Blood 109, 4045-4054 (2007).
15. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 113(Pt 10), 1661-1670 (2000).
16. Ubeda M, Habener JF. CHOP gene expression in response to endoplasmic-reticular stress requires NFY interaction with different domains of a conserved DNA-binding element. Nucleic Acids Res. 28, 4987-4997 (2000).
17. Lien YC, Kung HN, Lu KS, Jeng CJ, Chau YP. Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis. Histol. istopathol. 23, 1299-1308 (2008).
18. Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells, Cancer Invest. 22, 389-400 (2004).
19. Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: A link between iron metabolism and proliferation. Blood 104, 2967-2975 (2004).
20. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, Richardson DR. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53- independent mechanisms. Carcinogenesis 32, 732-740 (2011).